EP0178895A2

EP0178895A2 - Fluidized and rehydratable magaldrate compositions

Info

Publication number: EP0178895A2
Application number: EP85307392A
Authority: EP
Inventors: Chien-Chin Wu; Gerald Louis Reuter; Mark Ernest Coons
Original assignee: American Home Products Corp
Current assignee: Wyeth
Priority date: 1984-10-17
Filing date: 1985-10-15
Publication date: 1986-04-23
Anticipated expiration: 2005-10-15
Also published as: JPS61118321A; KR860003016A; DK167737B1; IE852493L; PT81309A; ES8801581A1; JPH06340533A; GR852506B; JPH0655677B2; DK473385D0; EP0178895A3; KR890000208B1; EP0178895B1; PT81309B; IE58636B1; DK473385A; JPH07103037B2; PH24706A; ES547910A0; DE3582002D1

Abstract

Fresh aqueous and powder forms of rehydratable antacid composition of magaldrate gel and a process for preparing same are described by the invention. The compositions are prepared from and contain precipitated and undried magaldrate gel and fluidizing amounts of a first and second fluidizer and the rehydratable powder form additionally contain a polyhydric alcohol. One fluidizer is provided by an aluminium hydroxide gel having colloidal properties and the second by a pharmaceutically acceptable citrate ion source including citric acid. The process and compositions are characterized in providing antacid compositions are fluid, resuspendible, pharmaceutically elegant suspension possessing high antacid capacity and stability at even elevated magaldrate concentrations in addition to the ability to fluidize stiff, paste-like magaldrate gel cakes.

Description

This invention relates to fluidized and rehydratable antacid compositions, more particularly to resuspeiidible, aqueous antacid suspension dosage forms for oral administration, to antacid powder compositions which are rehydratable to form aqueous antacid suspension dosage forms for oral administration and to methods for their preparation and use.
Antacids are widely used in the treatment of gastrointestinal disorders. Their effectiveness in promoting the healing of gastric and duodenal ulcers has been well documented. Essentially, antacids exert their positive effects by neutralizing the gastric acid secreted in the stomach. When the pH of stomach contents is raised above 3, most gastric acid is neutralized and the proteolytic activity of pepsin is inhibited. The recent elevation of antacids to a major therapeutic role, particularly in ulcer therapy, rather than a merely pallative role, has emphasized the importance of providing antacid products featuring a high neutralization (and buffer) capacity as well as a rapid rate of gastric acid neutralization. These features, particularly that of rapid rate of neutralization to the neutralization capacity of the antacid, define the more effective antacid in vivo since it is less likely that non-reacted antacids will be removed by normal gastric emptying.
Most antacids are available in both liquid and solid dosage forms. The liquid antacids, as aqueous suspensions, are, generally, more effective than the same antacids in solid dosage forms and are more commonly prescribed in the hospital. The greater effectiveness of liquid antacids is partially due to the large surface area available in liquid suspensions to react with gastric acid and partially due to,_ the great amount of colloidal particles in aqueous suspensions which can more easily reach the affected area where treatment is needed. Moreover, aqueous suspensions of undehydrated antacids are more reactive than dry or solid antacids.
While liquid antacids possess these advantages, the same require administration of relatively large volumes of liquid suspension. The ingestion of such large volumes is inconvenient, however, making the normal problem of assuring patient compliance outside the hospital environment even more difficult. Since high dose regimens of liquid antacid have recently been shown to be effective both in promoting the healing of duodenal ulcers and in preventing the acute upper gastrointestinal bleeding in critically ill patients, the use of regular liquid antacid suspensions with the usual solid antacid content in the 6-12 percent range has become even more impractical for such therapeutic indications.
The most widely used antacids can be described as mineral type, insoluble inorganic salts that are hydrated, possess colloidal properties, and contain, for example, aluminium, magnesium, bismuth and the like. Compounds of the described mineral variety in their freshly prepared, hydrated form and in suspensions therefrom provide some of the characteristcs desired in an antacid. To provide liquid antacids with a high neutralization capacity it is necessary to increase the solids concentration of the antacid components. Such increases in concentration, however, are accompanied at higher levels with exponential increases in viscosity, a loss in colloidal properties and a loss of fluidity or mobility. Even where fluidity is initially maintained or achieved, further requirements of pharmaceutically acceptable aqueous antacid suspensions call for a smooth (non-gritty) mouth feel and maintenance of a gel structure for both suspendibility and resuspendibility. In general, resuspendible, aqueous antacid suspensions are typically de-flocculated products which contain a deflocculant or suspending agent to arrest or control further agglomeration or flocculation and settling. In the absence of a deflocculant or suspending agent type additive, the antacid in a suspension forms a hard cake or a gel structure which can no longer be resuspended with its original desirable characteristics. The formation of such a cake or gel structure is independent of antacid concentration except for low antacid concentration.
Thus deflocculants and suspending agents have been frequently included in the formulation of aqueous antacid suspensions containing solid antacid concentrations in the range of about 6 to 12 percent to prevent caking. With the growing interest in providing antacid suspension dosage forms with a greater acid neutralizing capacity, means were sought to provide highly concentrated but fluid systems.
The cost of package, shipment and storage is more expensive for liquid than solid antacids. Therefore, it would be useful to develop an antacid powder which can be reversibly converted to its original colloidal state when wetted with water.
When magaldrate is precipitated by adding the magnesium salt to the alkali aluminate solution, it is a white gel containing 6-15% solids. The spray dried powder of this gel is not rehydratable to a smooth suspension. When wetted with water, the powder remains intact and can not go back to its colloidal state. This powder appears less effective and tastes gritty. Therefore, there is a need in the art for a totally rehydratable magaldrate powder which can be easily formulated, shipped to a distant facility, stored for a period of time and reconstituted to a colloidal suspension when it is needed.
It has now been found that the liquid magaldrate compositions disclosed in this application after addition of a polyhydric alcohol can be dehydrated to form a dry rehydratable magaldrate composition.
Suspensions of this invention may possess high antacid capacity and good mouth feel characteristics. Other advantages possible include rapid acid neutralization, reliably uniform reaction in acidic solutions, good fluidity, pourability and suspension characteristics and full resuspendibility under typical shelf-like conditions for a commercial aqueous antacid suspension,said advantages being retained at high concentrations.
Similar advantages can be achieved with the rehydratable compositions of this invention when admixed with water. Alternatively such rehydratable compositions may be formulated into chewable tablets with reduced grittiness when ingested.
In accordance with this invention there is provided aqueous antacid compositions characterized in providing a fluid, resuspendible, pharmaceutically elegant antaci.d suspension with high antacid capacity. In particular this invention provides an aqueous antacid composition in the form of a fluid, resuspendible, pharmaceutically acceptable suspension comprising precipitated and undried magaldrate gel and a fluidizing amount of a combination of an aluminium hydroxide gel having colloidal properties as a first fluidizer and a second fluidizer selected from citric acid, a pharmaceutically acceptable citrate ion source and mixturesthereof.
In further accordance with this invention there is provided rehydratable magaldrate compositions in solid powder form which when admixed with water form aqueous antacid compositions characterized in providing a fluid, resuspendible, pharmaceutically elegant antacid suspension with high antacid capacity. In particular this invention also provides an antacid composition in solid powder form providing when admixed with water a fluid, resuspendible, pharmaceutically acceptable antacid suspension said composition comprising a co-dried combination of magaldrate gel in its freshly precipitated wet statea polyhydric alcohol and a co-fluidizing amount of,as a first fluidizer, aluminium hydroxide gel having colloidal properties, and a co-fluidizing amount of a second fluidizer selected from at least one of the group consisting of citric acid and a pharmaceutically acceptable citrate ion source.
In another embodiment, the invention includes a method for producing aqueous antacid compositions of high antacid capacity and which are characterized in providing fluid, resuspendible pharmaceutically elegant antacid suspensions of magaldrate. Accordingly this invention provides a process for preparing an aqueous antacid composition which comprises mixing a precipitated and undried magaldrate gel, an aluminium hydroxide gel having colloidal properties as a first fluidizer and a second fluidizer selected from citric acid, a pharmaceutically acceptable citrate ion source and mixtures thereof, the combination of fluidizers being in a fluidizing amount to form a fluid, resuspendible pharmaceutically acceptable antacid suspension. The method comprises mixing a precipitated and undried magaldrate gel with a fluidizing combination of a first and second fluidizer. The first fluidizer is selected from an aluminium hydroxide gel having colloidal properties and the second fluidizer is selected from at least one of citric acid and a pharmaceutically acceptable citrate ion source. The method for producing the high antacid capacity, aqueous antacid compositions of the invention may be broadly approached and achieved, for example, either by prior concentration of the magaldrate gel cake into a high concentration paste followed by its fluidization with a fluidizing amount of the combination of the first and second fluidizer, or, by concentration of a fluid and relatively low concentration magaldrate gel cake previously mixed with a fluidizing amount of the combination of the first and second fluidizer.
In a further embodiment, the invention includes a method for producing rehydratable antacid compositions of high antacid capacity and which are characterised in providing fluid, resuspendible pharmaceutically elegant antacid suspensions of magaldrate. Accordingly this invention also provides a process for preparing a rehydratable antacid composition which when admixed with water forms a fluid resuspendible pharmaceutically acceptable suspension said process comprising mixing a precipitated and undried magaldrate gel, an aluminium hydroxide gel having colloidal properties as a first fluidizer, a second fluidizer selected from citric acid, a pharmaceutically acceptable citrate ion source and mixtures thereof, and a polyhydric alcohol, and drying the resulting admixture. The method comprises mixing a precipitated and undried magaldrate gel with a fluidizing combination of a first and second fluidizer and a polyhydric alcohol. The procedure is the same as described above except that the resulting admixture is then dehydrated or dried to form the desired rehydratable antacid composition.
The magaldrate of the invention is the precipitated, undried form of the antacid. This description refers to magaldrate gel which has not been previously dried to its hydrated, anhydrous form.
Magaldrate is a chemical combination of aluminum and magnesium hydroxide, corresponding approximately to the formula A1₅Mg_lo(OH)₃₁(SO₄)₂xH₂0, according to the official monograph USP XX, third supplement USP-NF, and has a molecular weight of about 1097.4. Magaldrate, also sometimes referred to in said monograph as aluminum magnesium hydroxide-sulfate, contains not less than 29.0 percent and not more than 40.0 percent of magnesium oxide (MgO) and the equivalent of not less than 18.0 percent and not more than 26.0 percent of aluminum oxide (A1₂0₃).
The preparation of magaldrate is described in U.S. Patent 2,923,660. A commercially suitable procedure is described in said patent, for example, beginning in column 2, line 40, although to maintain a low sodium content for the final product, the use of potassium oxide (or hydroxide) is preferred over the disclosed sodium oxide. Typically the magaldrate is precipitated to provide a 6% weight/volume mixture (fluid when fresh) and diluted to 3% for washing prior to concentration and formulation into a suspension providing a so called single strength neutralization capacity (ANC) of 13.5 to 15 meq per 5 milliliters of suspension which is equivalent to a magaldrate weight/weight concentration in the range of about 12 to 13 percent solids. At this concentration, unformulated, magaldrate is a paste-like gel. In one commercial embodiment sold under the RIOPAN trademark, the magaldrate is formulated with acacia gum to reduce the gel viscosity and achieve satisfactory fluidization. While acacia is suitable as a fluidizer for the so called single strength magaldrate product and is reported to be suitable for lowering the viscosity of a concentrated commercially aqueous antacid gel cake consisting of aluminum or magnesium hydroxide or a physical mixture of the two hydroxides, the same is not suitable for providing a magaldrate product providing greater than about 22 milliequivalents per 5 ml of ANC and the high antacid capacity composition of this invention. It is hardly surprising that the usefulness reported for acacia in liquifying aluminum or magnesium hydroxide antacids or mixtures thereof does not extend to magaldrate, since their crystal structures have been reported to be distinct. Thus, while magaldrate has a great similarity structurally to the naturally occurring minerals hydrotalcite and motukoreaite, and is believed to contain sulfate as the major interlayer, with a small amount of carbonate impurity, magnesium hydroxide is most similar to the mineral brucite and aluminum hydroxide has a disordered, amorphous polymeric structure. The physical mixtures of some aluminum and magnesium hydroxides have been reported to form hydrotalcite type structures on aging while retaining many brucite characteristics.
Mere fluidization or defloculation of an aqueous suspension dosage is, however, only one factor in the formulation of an aqueous antacid susension. Thus, no advantage arises from increased fluidization of more highly concentrated suspension if fluidization is achieved at the expense of resuspendibility or loss of rate or extent of acid neutralization capacity or antacid buffer capacity, immediately or upon aging. This concern is especially acute for an aqueous antacid suspension comprising magladrate as the predominant antacid because of its exceptional balance of desirable antacid properties within a single chemical entity - i.e., rapid reaction rate, prolonged buffering action within the therapeutically desired range and good acid- consuming capacity. With this invention, the desirable balance of magaldrate antacid properties is retained while the rheological properties of the magaldrate gels are significantly altered, thereby enabling the provision of concentrated, high antacid capacity magaldrate suspension. An additional benefit accompanying this invention is the uniformity of desirable rheological properties obtained which reduces or eliminates the batch to batch fine tuning frequently required to deal with the unpredictability usually inherent in the rheological properties of both fluidized and unfluidized magaldrate gels.
As previously described the magaldrate gel of this invention refers to precipitated magaldrate which has not previously been dried to its hydrated, anhydrous form. While the fluidizing combination contained in the composition of the invention may very well fluidize an aqueous mixture employing anhydrous magaldrate gel, a composition therefrom will not possess the desirable combination of suspension, resuspendibility, colloidal and antacid properties provided by the composition of the invention. Moreover, it is preferred in the composition of the invention to utilize freshly precipitated magaldrate gel since the use of older gels appears to require relatively higher proportions of the fluidizing combinations than the same composition comprising freshly precipitated magaldrate gels.
In contrast to most currently available antacid suspensions and to commercial magaldrate antacid suspensions which provide an ANC of about 13.5 meq/5m1, the composition of this invention readily provides an acid neutralization capacity (double strength) of at least 25-30 meq/5ml or of at least about 17-18% to about 20% weight/weight or about 18 to about 22% weight/volume. It will be appreciated that less concentrated suspensions such as those having an ANC of 13.5 meq/5 ml are, also, easily achievable by the composition and method of this invention. The upper limit to the ANC and concentration of the composition of this invention is only limited by the equipment available, but is believed to be on the order of 50-60 meq/5 ml.
The ratio on a dry basis of magaldrate to the fluidizing combination will range from about 25:1 to about 2:1, and preferrably from about 8:1 to about 4:1. For example, in a composition having 216 g magaldrate per liter of suspension, the 25:1 to 2:1 ratio would correspond to about 8.0 g/1 to about 104 g/liter of fluidizers.
The ratio on a dry basis of the first fluidizer, aluminiun hydroxide gel, calculated as aluminiun oxide to the second fluidizer will range from about 1:15 to about 1:1, preferrably from about 1:6 to about 1:2 and most preferrably in a range of about 1:4. For example, in a composition having 216 g magaldrate per liter of suspension in a ratio to fluidizers of 8:1 or 27 g/1 of fluidizers the 1:4 ratio of first fluidizer to second fluidizer would correspond to about 5.4 g/1 of first fluidizer and 21.6 g/1 of second fluidizer.
The polyhydric alcohols suitable for use in the rehydratable magaldrate compositions of this invention include those having from 2 to 6 free hydroxyl groups and include propylene glycol, glycerol, erythritol,threitol, ribitol, xylitol arabinitol, glycitol, sorbitol, mannitol and dulcitol. The polyhydric alcohol can be present in amounts of about 5 to about 10% by weight of the composition. Sorbitol is the preferred polyhydric alcohol.
In one embodiment, the invention relates to a method for providing or preparing aqueous antacid compositions of high antacid capacity and which are further characterized in providing fluid, resuspendible pharmaceutically elegant antacid suspensions of magaldrate. The method broadly comprises mixing a precipitated and undried magaldrate gel with a fluidizing combination of the first and second fluidizer of this invention. Moreover, mixing can be done prior or subsequent to concentration of the magaldrate gel.
Thus in one aspect the method of this invention comprises:

(a) mixing a low concentration of a precipitated and undried magaldrate gel with a fluidizing amount of a combination of an aluminum hydroxide gel having colloidal properties as a first fluidizer and a second fluidizer selected from at least one from the group consisting of citric acid and a pharmaceutically acceptable citrate ion source;
(b) concentrating the mixture of step (a) to a fluid high antacid capacity aqueous magaldrate suspension.

Alternatively, the steps of the method of the invention may be reversed so that the magaldrate gel is first concentrated to a concentration providing a high antacid capacity and then fluidized by mixing the concentrate magaldrate gel with a fluidizing amount of a combination of the first and second fluidizer of the invention.
In a preferred embodiment the method of the invention comprises:

(a) forming an aqueous mixture containing a fluidizing amount of a combination of an aluminiun hydroxide gel having colloidal properties as a first fluidizer and a second fluidizer selected from at least one from the group consisting of citric acid and a pharmaceutically acceptable citrate ion source;
(b) concentrating a precipitated and undried magaldrate gel to high antacid capacity; for example at least about 10%.
(c) incrementally and continuosly charging and mixing the concentrated magaldrate gel into a stream of the mixture containing said fluidizers thereby fluidizing the concentrated gel into a fluid suspension; and
(d) incrementally and continuously charging and mixing additional concentrated magaldrate gel into a continuously recycled stream of the increasingly concentrated fluidized suspension to provide a fluidized high antacid capacity magaldrate suspension.

The concentrations and proportions of materials used in the method of the invention are the same as those described for the composition of the invention and will be based on the magaldrate concentration of the fluidized suspension. Thus, the concentration of the magaldrate in step (b) of the hereinabove described method will exceed the final concentration of the suspensions. Also, as with the composition of the invention, the method of the invention preferably employs freshly precipitated magaldrate gel.
In the rehydratable powder embodiment, the invention relates to a method for providing or preparing aqueous antacid compositions of high antacid capacity and which are further characterized in providing rehydratable magaldrate compositions which when admixed with water form fluid, resuspendible pharmaceutically elegant antacid suspensions of magaldrate. The method broadly comprises mixing a precipitated and undried magaldrate gel with a polyhydric alcohol and a fluidizing combination of the first and second fluidizer of this invention. Moreover, mixing can be done prior or subsequent to concentration of the magaldrate gel.
Thus in one aspect the method of this invention comprises:

(a) mixing a low concentration of a precipitated and undried magaldrate gel with an admixture of a polyhydric alcohol and a fluidizing amount of a combination of an aluminiun hydroxide gel having colloidal properties as a first fluidizer and a second fluidizer selected from at least one of the group consisting of citric acid and a pharmaceutically acceptable citrate ion source;
(b) concentrating the mixture of step (a) to a fluid high antacid capacity aqueous magaldrate suspension.
(c) drying the mixture of step (b) as in a spray dryer.

Alternatively, the first two steps of the method of the invention may be reversed so that the magaldrate gel is first concentrated to a concentration providing a high antacid capacity. and then fluidized by mixing the concentrate magaldrate gel with a fluidizing amount of a combination of the first and second fluidizer of the invention.
In a preferred embodiment the method of the invention comprises:

(a) forming an aqueous mixture containing a polyhydric alcohol and a fluidizing amount of a combination of an aluminium hydroxide gel having colloidal properties as a first fluidizer and a second fluidizer selected from at least one from the group consisting of citric acid and a pharmaceutically acceptable citrate ion source;
(b) concentrating a precipitated and undried magaldrate gel to high antacid capacity e.g. at least about 10%.
(c) incrementally and continuosly charging and mixing the concentrated magaldrate gel into a stream of the mixture containing said fluidizers thereby fluidizing the concentrated gel into a fluid suspension; and
(d) drying the mixture of step (c) for example as in a spray dryer.

The composition of the invention can also and usually does include a number of pharmaceutically acceptable excipients which are conventional in the aqueous antacid suspension art and do not form part of the invention. Such excipients include one or more flavoring agents e.g. peppermint, etc; sweetening agents, e.g. saccharin, sorbitol, preservatives; sanitizers; body-building agents and the like.
The liquid composition of this invention whether fresh or rehydrated may also contain other therapeutically active substances such as antiflatulents, as for example, simethicone; algin derivatives for treatment of esophogeal reflux; analgesics such as acetaminophen, ibuprofen and protected aspirin; various antidiarrheal or parasympatholytic agents; antiulcer agents such as cimetidine, ranitidine and sucralfate; and others.
Compositions of this invention whether fresh or rehydrated are useful in the treatment of a variety of gastrointestinal disorders in man or animals. Typical of such disorders are hyperchlorhydria, peptic ulcer, gastric ulcer, duodenal ulcer, gastritis, esophagitis, hiatal hernia, and other digestive disturbances. As noted earlier, the composition of this invention are especially useful in the treatment of disorders that demand'the antacid to play a therapeutic role rather than a mere palliative role. The dosage form for the composition of this invention will normally be administered orally. In general, the therapeutic dosage of the composition can be determined by relationship to the ANC of same to that of known antacid dosage forms.
While not wishing to be bound by'any theory of invention, it is hypothesized that magaldrate prepared by the processes earlier described, contains small particles with a resulting greater surface area and higher surface charges. With a material such as just described, one in which it is essential to maintain the colloidal properties of the magaldrate to guarantee its most efficacious values over a useful shelf-life, control of viscosity is critical, and, is rendered more difficult in increasing concentrations. This control is achieved with a fluidizing amount of a combination of the first and second fluidizer whereby the second fluidizer apparently controls the surface charge of the magaldrate to create a desirable negative influence while the first fluidizer apparently enhances the arion absorption process and provides a competitive substrate with the magaldrate thereby maintaining an equilibrium of the negative influence. The negative influence, which can be determined by zeta potential measurements, thus fluidizes the magaldrate suspension to a mobilizable gel having an equilibrium which apparently provides for retention of desirable properties.
The invention may be further illustrated by the following examples. In Examples 1-3 the magaldrate gel (potassium base) was first concentrated to about a 24% w/w strength at which point it was a stiff immobile paste and then used to prepare the composition listed.

Example 1

This composition provided a magaldrate suspension according to the invention having 15.2% magaldrate solids providing approximately 20 meq/5m1 of ANC.
The citrate was dissolved in sufficient water to make an 80% w/w solution. The citrate solution and the aluminium hydroxide which is provided as a paste (12.5-13.5% A1₂0₃) were added to the concentrated magaldrate gel paste. The mixture was blended until it became a mobile liquid suspension. The other ingredients were then added to the suspension, the water being last to provide the final weight. The mixture was further blended to yield a homogeneous suspension. The fluid suspension was then further homogenized prior to filling the palatable suspension into 12 fluid ounce container for stability observation.
The suspension was evaluated over a four month period. At each time point, the suspension was found to have maintained its initial ANC, physical appearance, particle size distribution, mobility and resuspendibility (5 hand shakes).

Example 2

The magaldrate composition of the invention in this example provided a suspension having about 17.1% magaldrate solids with an approximate ANC of 24 meg/5ml.
The composition of this example was prepared as described in Example 1 and with the same results.

Example 3

The approximate ANC of this 20.1% w/w magaldrate composition is about 29 meq/5 ml.
The composition of this example again provided a fluid suspension and was prepared as described in Example 1 with the same results.

Example 4

A magaldrate suspension product, according to the invention, having an ANC of 30 meq/5ml or magaldrate 1080 mg/5m1 of suspension was prepared as follows. The formula given is for 1 liter (1.18Kg).

1. In a suitable tank equipped with a mixer, the sorbitol solution, 15.7g of the water and the citrate were combined and then mixed until a clear solution was obtained. The aluminium hydroxide gel was added and mixed until uniform and mixing continued until use.
2. Immediately before concentration of the magaldrate gel, 126g of the Step #1 mixture was added to a jacketed tank equipped with a stirrer. With continuous stirring, the magaldrate gel was concentrated on a rotary filter to a concentration of not less than 24% w/w into the mixture and cooling to 25° C was begun. After all the concentrated had been added the remainder of the Step #1 mixture was added with continuous stirring to achieve uniformity.
3. The Step #2 mixture was poured through a homogenizer into a jacketed tank with continuous stirring and continuous cooling to 25° C.
4. The remaining ingredients, except the water and monochloramine, were mixed in a separate container until uniform, after which, they were added to the magaldrate mixture and mixed until the xanthan gum was hydrated. Water was then added (with mixing) to bring the batch up to about 1.18 Kg.
5. Prior to filling the suspension, sufficient monochloramine was added to and mixed into the bulk material to provide at least 85 ppm in the suspension.
6. The suspension was then filled into sterilized containers which were capped, inverted and returned to the upright position.

The suspension of this example was subjected to repeated freeze-thaw cycles of 24 hours each, and after each cycle both the physical and antacid properties were retained. In contrast, a conventional magaldrate suspension at even 13.5 meq/5ml with acacia as the deflocculant did not retain all the properties after only one such cycle.

Example 5

Using the procedure described in Example 4, a magaldrate suspension, according to the invention, having an ANC of about 45 meq/5ml may be prepared.

Example 6

A magaldrate suspension, according to the invention, was prepared with the formula and procedure described in Example 4, but for the addition of simethicone to provide a suspension with an ANC of 30 meq/5ml and 30 mg/5ml of simethicone.

Example 7

In this experiment, two different freshly concentrated magaldrate gels at the percents indicated were employed to prepare suspensions with an ANC of 30 meq/5ml. The sorbitol, citrate, and aluminum hydroxide gel were added to a container equipped with a stirrer and mixing was begun. The magaldrate was added to the same container, preferrably incrementally and mixed until uniform. The saccharin and flavor were dispensed in the glycerin; after which, the xanthan gum was added and mixed until uniform. The flavored dispension was then added to the fluidized magaldrate with mixing until the mixture was uniform and the gum hydrated. Sufficient distilled water was added with mixing as was a quantity of the chlorine sanitizing solution to provide about 100 ppm chlorine. The suspensions (12) having an aluminum oxide ratio to citrate ranging from about 1:8.8 to about 1:3.95 were then filled into container. All formulations provided suspensions with the desired physical and antacid properties including resuspendibility.

Example 8

A typical formulation for the monochloramine solution referred to in some of the prior examples is as follows:
In the following examples a Buchi 190 Mini Spray Dryer was employed to dry the initial admixture containing magaldrate, the polyhydric alcohol and the first and second fluidizers. This model spray dryer is manufactured by Buchi Laboratoriums-Technik AG. Other spray dryers can be employed, however, such as those manufactured by Anhydro Company of Attleboro, Massachusetts and Niro Atomizer Inc., of Columbia, Maryland, so long as the spray dryer can process the relatively viscous admixture. The operating conditions for the spray dryer are customarily an inlet temperature of 130° C, an outlet temperature of 400° C and a wheel speed of 20,000 RPM.

EXAMPLE 9

In this example, a rehydratable magaldrate powder of this invention was prepared having the following formulation:
The above listed ingredients were processed as set forth below. Continuous agitation must be maintained throughout the processing.

Step 1. Add the sorbitol solution, USP to a suitable tank equipped with a stirrer.
Step 2. Add the potassium citrate, NF then mix until uniform.
Step 3. Concentrate the magaldrate gel sulfate, potassium base to not less than 24% magaldrate and add to the tank in Step #2
Step 4. When approximately half of the concentrated gel has been added to the batch, add the aluminum hydroxide gel to the mixture of Step #3.
Step 5. When all of the gel has been added, obtain an assay of the magaldrate content and adjust the quantities of all ingredients to the theoretical ratios. Mix for 5 minutes after each addition.
Step 6. Spray dry the Step #5 gel mixture at the following conditions:

EXAMPLE 10

In this example, the rehydratable magaldrate powder of Example 9 was reconstituted into a stable, liquid magaldrate formulation for oral administration containing 15 milliequivalents of magaldrate per 5 milliliters of formulation. In this and the following examples the monochloroamine solution employed was a stock solution prepared in the following manner from the listed ingredients.
The calcium hypochlorite, 60% was added to 1.97 kg water and mixed with vigorous stirring for at least 10 minutes. The ammonia solution was added to 28.0 g water and stirred briefly. The ammonia solution was then added to the chlorine solution and mixed with vigorous stirring until uniform and filtered after an hour.
Using the rehydratable magaldrate powder as prepared in Example 9, the monochloroamine solution prepared as shown above, and the other ingredients shown below, the reconstituted magaldrate was prepared as follows:
THe above listed ingredients were processed as set forth below. During processing the equipment should be kept clean to minimize bacterial growth and the processing carried out as aseptically as practicable. The finished suspension should be kept in a closed tank to minimize monochloramine losses during filling. Also continuous stirring must be maintained throughout.

Step 1. Place 700 grams of chlorinated water into a suitable compounding tank equipped with a mixer.
Step 2. Slowly add the magaldrate powder with constant mixing, mix for approximately 1 hours or until completely hydrated.
Step 3. To a separate container equipped with an agitator, add the Glycerin, saccharin, xanthan gum, and the peppermint flavor and mix until uniform, then cool to 30° C or less.
Step 4. Add the Step #3 mixture to the Step #2 mixture and mix until the xanthan gum is hydrated.
19Step 5. Add sufficient water to bring the batch to 1.0774 kg.
Step 6. Pass the suspension through a homogenizer at 1000 PSIG+100 into a jacketed tank with continuous stirring.
Step 7. Immediately prior to the start of filling, add monochloramine at 6,000 PPM to achieve 100 PPM (NLT 85) by assay in the bulk suspension and mix for 30 minutes. The suspension of step 7 should be below 25° C before adding the monochloroamine.
Step 8. Fill the finished suspension into bottles with screw cap which may have been previously sterilized.
Step 9. Invert each bottle of suspension for not less than 2 seconds (NMT 1 hour), then return to the upright position.

EXAMPLE II

In this example, the rehydratable magaldrate powder of Example 9 was reconstituted into a stable, liquid magaldrate formulation for oral administration containing 30 milliequivalents of magaldrate per 5 milliliters of formulation.
Using the rehydratable magaldrate powder as prepared in Example 9 the monochloroamine solution prepared as shown in Example 10, and the other ingredients shown below, the reconstituted magaldrate was prepared as follows:
The above listed ingredients were processed in the same manner as in Example 10 except that in Step 1 only 500 grams of chlorinated water was placed in the mixer, the simethicone was added and mixed after Step 4, and in Step 5, sufficient water was added to bring the batch only to 1.0774 kg.

EXAMPLE 12

In this example, a rehydratable magaldrate composition of this invention was prepared having the following formulation to produce 100 kg of magaldrate powder.

Inlet Temperature - 400°C
Outlet Temperature -130° C
Atomization Wheel Speed 16,000 RPM

Magaldrate concentration of resultant powder would typically range from 65-68%.

EXAMPLE 13

A magaldrate chew tablet prepared from the rehydratable powder of Example 12sufficient to make 1000 directly compressed tablets is shown below:
Other examples of directly compressible tabletting ingredients for this product would be dextrates, sorbitol and other directly compressible sugars such a Di-Pac, a compressible sucrose made by Amstar Corporation of New York, N.Y. Zinc Stearate could also be substituted as a lubricant for magnesium stearate. A lozenge dosage form rather than a chew tablet can be prepared using suitable tabletting ingredients such as sorbitol.

EXAMPLE 14

Magaldrate rehydratable granules can be prepared from the rehydratable powder of Example 12to provide 1 kilogram of granulation as follows
The above powders are wet massed in a suitable mixer by the addition of water. The resultant granulation is wet sized, dried in a fluidized bed dryer and then dry sized. The potency of the above resultant granulation is 46.9% magaldrate.

EXAMPLE 15

The rehydratable magaldrate granules as prepared in Example 14 can be packaged to provide a 30 milliequivalent magaldrate dose per 5 milliliters of oral dosage form as follows:
To the above blend, one would add 5 ml water and shake to rehydrate. This would give a single 30 mEq dose.

EXAMPLE 16

The rehydratable magaldrate granules as prepared in Example 14 can also be packaged with milk solids to provide a 30 milliequivalent magaldrate dose per 20 milliliters of oral dosage form as follows:
Again for a single dose, 20 ml of water would be added to the above blend to allow for rehydration. The milk solids are added to give a creamier and more pleasant tasting product.

EXAMPLE 17

The rehydratable magaldrate granules as prepared in Example 14 can further be packaged with other pharmaceutical agents such as antidiarrheal agents, i.e. adsorbents and anticholinergics, as follows:
The mixture would be rehydrated and resuspended with 20 ml water for a single dose (ANC of 15 mEq).
The packaging of the compositions of Examples 15-17 preferably would be of the foil or hermetic unit type.
Additional formulation of rehydratable magaldrate powder are shown in Table 1.
Of the rehydratable magaldrate powder compositions of Table 1, Formula 8 gave the best mouth feel in terms of no grittiness and Formula 6 was next best. All of the formulas were readily rehydratable.

Claims

1. An aqueous antacid composition in the form of a fluid, resuspendible, pharmaceutically acceptable suspension comprising precipitated and undried magaldrate gel and a fluidizing amount of a combination of an aluminium hydroxide gel having colloidal properties as a first fluidizer and a second fluidizer selected from citric acid, or a pharmaceutically acceptable citrate ion source and mixtures thereof.

2. An antacid composition in solid powder form providing when admixed with water a fluid, resuspendible, pharmaceutically acceptable antacid suspension said composition comprising a co-dried combination of magaldrate gel in its freshly precipitated wet state, a polyhydric alcohol and a co-fluidizing amount of, as a first fluidizer, aluminium hydroxide gel having colloidal properties, and a co-fluidizing amount of a second fluidizer selected from at least one of the group consisting of citric acid and a pharmaceutically acceptable citrate ion source.

3. A composition according to Claim 1 or Claim 2 wherein the second fluidizer is selected from at least one of citric acid, potassium citrate, sodium citrate and aluminium citrate.

4. A composition according to Claim 1 or Claim 2 wherein the second fluidizer is potassium citrate.

5. A composition as claimed in any one of Claims 1 to 3 wherein the ratio on a dry basis of magaldrate to the combination of fluidizers rangesfrom about 25:1 to 2:1.

6. A composition as claimed in any one of Claims 1 to 4 wherein the ratio on a dry basis of the first fluidizer to the second fluidizer ranges from about 1:15 to about 1:1.

7.- A composition as claimed in Claim 1 or Claim 2 comprising potassium citrate as the second fluidizer and wherein the ratio on a dry basis of magaldrate to the combination of fluidizers is about 8:1 to about 4:1 and the ratio on a dry basis of the first fluidizer to the second fluidizer is about 1:6 to about 1:2.

8. A composition as claimed in any one of Claims 1 to 7 comprising at least about 10% w/v of said magaldrate when in suspension.

9. A composition as claimed in any one of Claims 1 to 7 comprising at least about 18% w/v of said magaldrate when in suspension.

10. A composition as claimed in any one of Claims 2 to 9 in which the polyhydric alcohol contains 2 to 6 free hydroxy groups.

11. A composition as claimed in any one of Claims 2 to 9 wherein the polyhydric alcohol is sorbitol.

12. A process for preparing an aqueous antacid composition which comprises mixing a precipitated and undried magaldrate gel,an aluminium hydroxide gel having colloidal properties as a first fluidizer and a second fluidizer selected from citric acid, a pharmaceutically acceptable citrate ion source and mixtures thereof, the combination of fluidizers being in a fluidizing amount to form a fluid, resuspendible pharmaceutically acceptable antacid suspension.

13. A method as claimed in Claim 12 in which prior to mixing with the fluidizers, said magaldrate gel is in the form of a stiff and non-flowing paste.

14. A method as claimed in Claim 12 in which prior to mixing with the fluidizers, said magaldrate gel is in a dilute concentration and after mixing with the fluidizers said aqueous mixture is concentrated by removing water.

15. A method for preparing an aqueous antacid composition of magaldrate in the form of a fluid, resuspendible, pharmaceutically acceptable suspension comprising the steps of: _

(a) forming an aqueous mixture containing a fluidizing amount of a combination of an aluminium hydroxide gel having colloidal properties as a first fluidizer and a second fluidizer selected from citric acid, a pharmaceutically acceptable citrate ion source and mixtures thereof;

(b) concentrating a precipitated and undried magaldrate gel to a weight/volume concentration of at least 10%;

(c) incrementally and continuously charging and mixing the concentrated magaldrate gel into a stream of the mixture containing said fluidizer thereby fluidizing the concentrated gel into a fluid suspension; and

(d) incrementally and continuously charging and mixing additional concentrated magaldrate gel into a continuously recycled stream of the increasingly concentrated fluidized suspension to provide a fluidized high antacid capacity magaldrate suspension.

16. A process for preparing a rehydratable antacid composition which when admixed with water forms a fluid resuspendible pharmaceutically acceptable suspension said process comprising mixing a precipitated and undried magaldrate gel, an aluminium hydroxide gel having colloidal properties as a first fluidizer, a second fluidizer selected from citric acid, a pharmaceutically acceptable citrate ion source and mixtures thereof, and a polyhydric alcohol, and drying the resulting admixture; the combination of fluidizers being a fluidizing amount.

₁₇. A method for preparing a rehydratable magaldrate composition characterized in providing a fluid, resuspendible, pharmaceutically elegant suspension comprising the steps of:

(a) forming an aqueous mixture containing a polyhydric alcohol and a fluidizing amount of a combination of an aluminium hydroxide gel having colloidal properties as a first fluidizer and a second fluidizer selected from the group consisting of citric acid, a pharmaceutically acceptable citrate ion source and mixtures thereof;

(d) drying the admixture of magaldrate gel and first and second fluidizer.

1. A process for preparing an aqueous antacid composition which comprises mixing a precipitated and undried magaldrate gel, an aluminium hydroxide gel having colloidal properties as a first fluidizer and a second fluidizer selected from citric acid, a pharmaceutically acceptable citrate ion source and mixtures thereof, the combination of fluidizers being in a fluidizing amount to form a fluid, resuspendible pharmaceutically acceptable antacid suspension.

2. A process as claimed in Claim 1 in which prior to mixing with the fluidizers, said magaldrate gel is in the form of a stiff and non-flowing paste.

3. A process as claimed in Claim 1 in which prior to mixing with the fluidizers, said magaldrate gel is in a dilute concentration and after mixing with the fluidizers said aqueous mixture is concentrated by removing water.

4. A.process for preparing an aqueous antacid composition of magaldrate in the form of a fluid, resuspendible, pharmaceutically acceptable suspension comprising the steps of:

5. A process for preparing a rehydratable antacid composition which when admixed with water forms a fluid resuspendible pharmaceutically acceptable suspension said process comprising mixing a precipitated and undried magaldrate gel, an aluminium hydroxide gel having colloidal properties as a first fluidizer, a second fluidizer selected from citric acid, a pharmaceutically acceptable citrate ion source and mixtures thereof, and a polyhydric alcohol, and drying the resulting admixture; the combination of fluidizers being-a fluidizing amount.

6. A process for preparing a rehydratable magaldrate composition characterised in providing a fluid, resuspendible, pharmaceutically elegant suspension comprising the steps of:

(d) drying the admixture of magaldrate gel and first and second fluidizer.

7. A process according to any one of Claims 1 to 6 wherein the second fluidizer is selected from at least one of citric acid, potassium citrate, sodium citrate and aluminium citrate.

8. A process according to any one of Claims 1 to 6 wherein the second fluidizer is potassium citrate.

9. A process as claimed in any one of Claims 1 to 8 wherein the ratio on a dry basis of magaldrate to the combination of fluidizers ranges from about 25:1 to 2:1.

10. A process as claimed in any one of Claims 1 to 8 wherein the ratio on a dry basis of the first fluidizer to the second fluidizer ranges from about 1:15 to about 1:1.

11. A process as claimed in any one of Claims 1 to 6 comprising potassium citrate as the second fluidizer and wherein the ratio on a dry basis of magaldrate to the combination of fluidizers is about 8:1 to about 4:1 and the ratio on a dry basis of the first fluidizer to the second fluidizer is about 1:6 to about 1:2.

12. A process as claimed in any one of Claims 5 to 11 in which the polyhydric alcohol contains 2 to 6 free hydroxy groups.

13. A process as claimed in any one of Claims 5 to 11 wherein the polyhydric alcohol is sorbitol.

14. A process as claimed in any one of Claims 1 to 13 in which the magaldrate comprises at least about 10% w/v when in suspension.

15. A process as claimed in any one of Claims 1 to 13 in which the magaldrate comprises at least about 18% w/v when in suspension.